Background: We evaluated the efficacy and safety of risk-adapted, proton-based stereotactic body radiation therapy (SBRT) for liver metastases from solid tumors. Methods: This single-arm phase II single institutional study (NCT01239381) included patients with limited extrahepatic disease, 800 mL or greater of uninvolved liver, and no cirrhosis or Child-Pugh A, who had received proton-based SBRT to one to four liver metastases from solid tumors. Treatment comprised 30 to 50 Gray equivalent (GyE) in five fractions based on the effective volume of liver irradiated. Sample size was calculated to determine if local control (LC) at one year was greater than 70%. The cumulative incidence of local failure was used to estimate LC. The association of tumor characteristics, including genetic alterations in common cancer genes such as BRAF, EGFR, HER2, KRAS, NRAS, PIK3CA, and TP53 with local tumor control, was assessed. All statistical tests were two-sided. Results: Eighty-nine patients were evaluable (colorectal, n ¼ 34; pancreatic, n ¼ 13; esophagogastric, n ¼ 12; other, n ¼ 30). Median tumor size was 2.5 cm (range ¼ 0.5-11.9 cm). Median dose was 40 GyE (range ¼ 30-50 GyE), and median follow-up was 30.1 months (range ¼ 14.7-53.8 months). There was no grade 3 to 5 toxicity. Median survival time was 18.1 months. The one-and three-year LC rates were 71.9% (95% confidence limit [CL] ¼ 62.3% to 80.9%) and 61.2% (95% CL ¼ 50.8% to 71.8%), respectively. For large tumors (6 cm), one-year LC remained high at 73.9% (95% CL ¼ 54.6% to 89.8%). Mutation in the KRAS oncogene was the strongest predictor of poor LC (P ¼ .02). Tumor with both mutant KRAS and TP53 were particularly radioresistant, with a one-year LC rate of only 20.0%, compared with 69.2% for all others (P ¼ .001).
Conclusions: We report the largest prospective evaluation to date of liver SBRT for hepatic metastases, and the first with protons. Protons were remarkably well tolerated and effective even for metastases that were 6 cm or larger. KRAS mutation is a strong predictor of poor LC, stressing the need for tumor genotyping prior to SBRT and treatment intensification in this patient subset.
Management of liver-dominant metastatic disease remains a challenging clinical problem. While surgery can be potentially curable for patients with hepatic-only metastatic disease from colorectal cancer, the curability of other malignancies has not been as well demonstrated. Furthermore, many patients may not be amenable to surgical resection for either technical or medical reasons. Stereotactic body radiation therapy (SBRT) uses a small number of fractions (1) (2) (3) (4) (5) to deliver high or ablative daily doses through precise anatomic target definition and sophisticated image guidance. Prior reports of SBRT for liver tumors and metastases have demonstrated high rates of local control (LC) of more than 70% at one year (1) (2) (3) (4) (5) (6) (7) (8) . However, the majority of prospective series have treated patients with smaller tumors, generally less than 3 cm, and mostly less than 6 cm in maximum dimension.
Treating large tumors in the liver safely and effectively remains an important clinical need. One approach to treat liver tumors is to individualize the radiation dose delivered to the tumor based on what is a safe dose to the uninvolved liver. In a prospective multi-institutional phase I study (5) , SBRT dosing was determined based on a radiobiologic parameter known as "effective volume radiated," or Veff. Patients with a lower liver Veff, meaning less of the liver receiving radiation, received higher doses of radiation, and patients with higher liver Veff received lower doses of radiation. Using this method, there were no cases of radiationinduced liver disease (RILD), and the one-year LC rate was 71%.
Proton beam therapy utilizes charged particles instead of high-energy photons. Protons offer a distinct clinical advantage over photon-based radiation (9, 10) . Photons deposit their energy along its beam path and continue to deposit dose beyond the tumor. This exit dose leads to a larger volume of liver irradiated. In contrast, protons deposit at a defined depth without exit dose, leading to a decreased volume of liver radiated. Protons theoretically can allow for improved dosing for liver tumors when using a Veff-based individualized dosing strategy due to the greater volume of liver spared from radiation dose.
While radiation is often able to eradicate localized disease, especially when given in high ablative doses, there remains a great need to identify radioresistant tumors. Such radioresistance biomarkers would facilitate the development of treatment intensification strategies to improve local control. There exists a paucity of clinical data to define the importance of candidate markers of radioresistance such as KRAS, BRAF, or NFE2L2 (11) (12) (13) (14) (15) (16) .
In this single institution phase II trial, we evaluate the feasibility and efficacy of a risk-adapted dosing strategy using proton-based SBRT for liver metastases, and we evaluate the impact of tumor size and genotype on local disease control.
Methods

Study Population
Patients were enrolled onto a prospective clinical trial (NCT01239381) approved by the Dana-Farber/Harvard Cancer Center Institutional Review Board. Adult patients age 18 years or older were required to have liver metastases from a solid tumor (including multifocal hepatocellular carcinoma). Patients were required to have no extrahepatic disease, or limited extrahepatic disease if stable for at least three months and dominant burden of disease was in the liver. Expected survival had to exceed three months. Multinodular tumors (up to four) were permitted. No upper tumor size limit was required, but patients were required to have 800 mL or more of uninvolved liver. Patients may have had prior systemic therapy (including chemotherapy, biological therapy) or liver-directed therapy including transarterial chemoembolization, radiofrequency ablation, or microwave ablation three or more weeks prior to first radiation treatment. Hormonal therapies were permitted to be continued through treatment. No liver-directed radiation therapy was permitted. However, prior upper abdominal radiation was allowed if the liver was not the target. Patients must have an Eastern Cooperative Oncology Group performance status of 0 to 2. Patients were required to have no cirrhosis or Child-Pugh A cirrhosis. Adequate organ and marrow function were required and defined as absolute neutrophil count 750/mL or higher; platelets 25 000/mL or higher; total bilirubin four or more times the institutional upper limit of normal (ULN); transaminases six or more times the institutional ULN; creatinine 2 mg/dl or more. Written informed consent was obtained from all protocol patients prior to initiation of any study procedures.
Simulation
All patients underwent simulation with four-dimensional computer tomography (CT) with intravenous contrast. A clinical target volume (CTV) expansion of 0 to 1 cm around the gross target volume was used at the discretion of the treating physician. The precise CTV varied based on the confidence of the treating physician to identify the borders of the lesion on imaging. The setup uncertainty margin was customized based on the individual motion management strategy used and ranged from 0.5 to 1.0 cm. Fiducials were recommended, and respiratory gating was performed based on previously published guidelines (17) .
Dose Prescription and Normal Tissue Constraints
The relative biological effectiveness (RBE) of protons was set at 1.1 per institutional standard. Thus, the dose unit Gray equivalent (GyE) is a proton dose in Gy x RBE of 1.1. Patients were planned to receive five fractions. Radiation dose was based on Veff of liver minus gross tumor volume (GTV). Patients with a Veff of 0.22 or lower received 50 Gy, Veff of 0.22 to 0.50 received 40 Gy, and Veff of 0.51 or higher received 30 Gy. Nonliver normal tissue constraints were spinal cord maximum dose of 22 GyE, stomach dose of 30 GyE to less than 0.5 mL, bowel (including duodenum, small bowel, large bowel) dose 30 GyE to less than 0.5 mL, combined kidney volume receiving over 15 Gy less than 2/3 or maximum dose of 7 GyE to 90% of one functional kidney. A heart maximum dose of 20 GyE and a chest wall dose of 40 GyE to less than 2 mL were recommended.
Treatment
All treatments were delivered using passively scattered protons at the Francis H. Burr Proton Center at Massachusetts General ARTICLE Hospital (235 MeV cyclotron). Daily imaging for tumor localization was required.
Genotyping
Mutational analysis of tumor specimens was performed using a previously described polymerase chain reaction-based method, SNaPshot (18) . Tumor genotyping was performed on formalinfixed, paraffin-embedded tissue as part of routine patient care. This assay and its subsequently implemented next-generation sequencing-based platform queries common mutations simultaneously across genes frequently altered in cancers, including KT1, APC, BRAF, CTNNB1, EGFR, HER2, IDH1, KIT, KRAS, MAP2K1, NOTCH1, NRAS, PIK3CA, PTEN, and TP53 (Supplementary Table 1 , available online).
Follow-up
Patients had follow-up visits every three months, with CT scans every three to six months for the first two years. For years 3 to 5, patients had follow-up visits every six months. Toxicity was scored using the common terminology criteria (CTC) version 3.0 and was counted only if possibly, probably, or likely related to radiation in attribution. Progression was determined by the interpreting radiologist and confirmed by the treating physician.
Statistics
The study was designed to determine if a LC rate greater than 70% at one year, previously associated with individualized photon-based SBRT for liver metastases (5), can be achieved. LC was defined as the absence of local failure due to tumor growth/ regrowth in any direction beyond that present on the pretreatment (baseline studies of the treated lesion(s) by RECIST 1.0) (19) . When more than one tumor was treated in a given patient, the patient was coded as local failure once the protocolspecified failure criteria were met in at least one tumor. New intrahepatic tumors outside of the radiation field were scored as elsewhere failures. LC, overall survival (OS), and progressionfree survival (PFS) times were calculated starting from the first day of radiation. LC was estimated from the cumulative incidence function of local failure, treating death as a competing risk. Univariate comparisons of LC by tumor and molecular characteristics were made using Gray's test of a two-sided hypothesis. The OS of a patient still alive at the time of last followup was censored. PFS was measured until a patient had documented progression in any site or died, whichever event was earlier, or otherwise was censored at the date of last follow-up. OS and PFS rates were estimated by the Kaplan-Meier method. Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC) and R version 3.3.1 (R Foundation for Statistical Computing, Vienna, Austria). All statistical tests were two-sided, and a P value of less than or equal to .05 was considered statistically significant.
Results
Study Cohort
Ninety-one patients were enrolled from October 2010 through February 2015. Two patients were excluded from analysis because they never started treatment because of decline in performance status and symptomatic extrahepatic progression prior to treatment. Patient and tumor characteristics for the 89 analyzable patients are shown in Table 1 and Supplementary  Table 2 (available online) . There were 34, 13, 12, and 30 patients with colorectal, pancreatic, esophagogastric, and other histologies, respectively. Notable characteristics include: Most patients had one liver target lesion (61.8%). The entire cohort was treated collectively for 143 individual tumors, with a median tumor size of 2.5 cm (range ¼ 0.5-11.9 cm), and there were 23 patients with at least one tumor 6 cm or larger in diameter. The majority of patients had adenocarcinoma (n ¼ 70), and colorectal carcinoma (CRC; n ¼ 34) was the most common cancer type. The clinically interesting subsets of CRC and those with large tumors (6 cm) are described separately in Table 1 and Supplementary Table 2 (available online). The median radiation dose was 40 GyE (range ¼ 30-50 GyE). Even among the 23 patients with the largest metastasis being 6 cm or larger, most (82.6%) were able to receive at least 40 GyE.
Toxicity
Seventy-eight patients (87.6%) experienced at least one radiation-related toxicity while on study, most commonly fatigue (68.5%), dermatitis (47.2%), abdominal pain (23.6%), anorexia (15.7%), and nausea (13.5%) ( Table 2 ). There were no grade 3 to 5 radiation-related toxicities.
Disease-Specific Outcomes and Failure Analysis
Median follow-up time for survivors was 30.1 months (range ¼ 14.7-53.8 months). Cumulative one-and three-year LC rates were 71.9% (95% confidence limit [CL] ¼ 62.3% to 80.9%) and 61.2% (95% CL ¼ 50.8% to 71.8%), respectively ( Figure 1A ). For the entire cohort, the median PFS time was 3.7 months (95% CL ¼ 3.0 to 6.8 months), with one-and three-year PFS rates of 24.7% (95% CL ¼ 16.3% to 30.4%) and 9.2% (95% CL ¼ 4.0% to 16.9%), respectively ( Figure 1B) . The median survival time was 18.1 months (95% CL ¼ 14.3 to 21.0 months), with one-, two-, and three-year OS rates of 66.3% (95% CL ¼ 55.5% to 75.1%), 35.9% (95% CL ¼ 25.8% to 46.2%), and 20.8% (95% CL ¼ 12.4% to 30.8%), respectively ( Figure 1C) .
The patterns of site of first failure for the entire cohort, the CRC subgroup, and patients with largest tumor of 6 cm or larger are shown in Supplementary Table 3 (available online). Of note, 14.6% of the entire cohort, 20.6% of CRC patients, and 4.3% of patients with largest tumor of 6 cm or larger remained free from progression anywhere. For the entire cohort, 4.5% of patients first experienced local failure only, 12.4% experienced local failure with other progression, and 68.5% first experienced nonlocal progression only.
Univariate associations with LC were explored for the entire cohort (Table 3) . CRC patients experienced the most rapid local progression, compared with patients with other adenocarcinoma primaries and nonadenocarcinoma histologies (P ¼ .046) (Figure 2A ). The associated one-and three-year LC rates were 58.8% (95% CL ¼ 42.8% to 75.6%) and 44.7% (95% CL ¼ 28.8% to 64.5%), respectively. However, PFS and OS times were comparable with the entire cohort (Supplementary Figure 1, available  online) .
Disease status at enrollment (progressing vs responding, stable, or metastatic), number of tumors (multiple vs single), largest tumor size (6 cm vs <6 cm), and total dose to GTV (50 vs 30-40 GyE) were not associated with LC. The excellent LC for large tumors of 6 cm or larger is highlighted in Figure 2B , with one-and three-year rates being 73.9% (95% CL ¼ 54.6% to 89.8%) and 65.2% (95% CL ¼ 43.1% to 86.1%), respectively. However, PFS and OS times were worse when compared with smaller tumors (Supplementary Figure 2 , available online).
Mutational Analysis
Mutational data were available for 60 patients, but three patients with primary liver cancer, which generally carries a much Table 4 , available online). The presence of a KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local treatment outcome, with a one-year LC rate of 42.9% vs 72.1% for tumors without detected mutation (P ¼ .02) ( Figure 3A , Table 3 ). The presence of a TP53 hotspot mutation was associated with a one-year LC rate of 46.2%, compared with 70.5% in all other patients (P ¼ .08) ( Figure 3B ). Patients with both KRAS and TP53 mutations comprised the worst subgroup, with a one-year LC rate of only 20.0% vs 69.2% for all other genotypes (P ¼ .001) ( Figure 3C ). Further subset analysis was limited by the small number of patients per histology. In the subset comprising CRC patients (n ¼ 27), KRAS-mutant tumors had a one-year LC rate of 57.1% (95% CL ¼ 24.3% to 92.4%), which was not statistically different from the 28.6% rate (95% CL ¼ 5.9% to 84.7%) in the non-CRC group (P ¼ .20) (Supplementary Figure 3A, available online) . In contrast, patients with KRAS wild-type CRC had worse LC than patients with non-CRC (P ¼ .005) (Supplementary Figure 3B , available online), consistent with the overall poor LC rate seen for this histology (Figure 2A ). All five tumors that had a double mutant KRAS and TP53 genotype failed locally, three of which were CRC and two were of pancreatic adenocarcinoma histology. Overall, of eight pancreatic adenocarcinomas, two were wild-type for KRAS and remained locally controlled, while six had KRAS mutations and four of these recurred.
Discussion
With 89 patients, this study represents the largest prospective evaluation to date of liver SBRT for hepatic metastases, and the first with protons. Our results suggest that proton-based liver SBRT is effective and well tolerated, with no grade 3þ toxicity observed. The dosimetric advantages of protons compared with photons are exemplified by the ability to treat and control liver tumors sized 6 cm or larger without serious adverse events. In contrast, previous reports of photon SBRT generally excluded such large lesions (1-4,6-8) .
The delivery of high radiation doses to large tumors with protons is facilitated by a risk-adaptive strategy using Error bars represent 95% confidence intervals.
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individualized, liver Veff-dependent dosing. This strategy allows dosing of large tumors as it does not require a minimal amount of liver to be spared a certain dose of radiation. This was similarly employed in a phase I study of individualized SBRT for liver metastases (5) . In 68 treated patients, the median dose was 41.8 Gy. There were no cases of RILD or other grade 3 to 5 toxicity. However, in contrast to our study, smaller tumors (<75.2 mL) had lower local failure rates than larger tumors. This individualized dosing strategy has been adopted for the Radiation Therapy Oncology Group (RTOG) 1112 protocol, which is evaluating the role of SBRT in unresectable primary liver tumors.
There is little data on predictors of local failure after SBRT (5,7). Unexpectedly, we observed that oncogenic mutations in KRAS were the strongest predictor of local failure, with irradiated tumors rapidly progressing within only six months of treatment. While the in vitro radioresistance of tumor cells harboring mutated KRAS has been recognized for many years (14, 20) , clinical studies in support of this association have been sparse and included small case numbers or the addition of chemotherapy to radiation (12, 21, 22) . It is becoming increasingly clear that KRAS-mutated cancers are heterogeneous so that additional biomarkers are needed to predict treatment responses (23) . Interestingly, multivariable testing revealed that the combination of mutated KRAS with hotspot mutations in the TP53 tumor suppressor define a subset of extremely radioresistant tumors. Notably, whether abrogation of wild-type p53 function in and of itself leads to radioresistance has been controversial (24) (25) (26) (27) . A better understanding of how hotspot mutants of TP53, which can have oncogenic properties (28) , modify the radiosensitivity of KRAS-mutated tumors is an important goal of ongoing investigations. Molecular targets for mutant KRAS-specific radiosensitization, such as PKC, Aurora B, or Chk1, are emerging and could be translated into patients in the near future (11, 29, 30) .
Limitations of this study include the enrollment of a clinically heterogeneous cohort with a wide range of tumor histologies and 
relatively low radiation dosing. CRC metastases exhibited worse LC than other tumors. This mirrored reported higher local failure rates of pulmonary CRC metastases treated with SBRT. For example, in the Stanford experience, the two-year LC rate after SBRT for pulmonary CRC metastases was 57.8% vs 90.1% for all other histologies (P < .01) (31) . Whether heterogeneity affected the influence of tumor genotype on LC in our mutational analysis could not be reliably assessed because of the small number of patients for each tumor type/histology. To this end, how the impact of KRAS mutation status on local treatment outcome may vary between tumor types and whether co-occurring mutations that predict local failure differ will be interesting topics for future investigations. Testing predictive markers such as the Radiosensitivity Index (RSI) may also be a useful strategy to identify radioresistant tumors across different histologies (32) . Further, our one-year local control rate of 72% is relatively low. In a study presented in 2014, a MEDLINE search was performed and 13 papers were identified that treated liver metastases with SBRT (33) . Using the linear-quadratic formula to compare the intensiveness of schedules and assuming a tumor a/b of 10 Gy, the investigators found that radiation schedules with a biologically effective dose (BED) of greater than 100 Gy had a two-year LC rate of 93%, while a BED of 100 Gy or less was associated with an LC rate of 70%. The BEDs of the 50 Gy, 40 Gy, and 30 Gy groups used in this study are 100 Gy, 72 Gy, and 48 Gy, respectively, indicating that none of the three doses used in the current study exceeded a BED of 100 Gy. This raises the possibility of radiation dose escalation as a potential strategy to improve LC and overcome radioresistance. However, while this strategy may work well with small tumors, it is difficult to achieve substantially higher doses using photon-based therapies. Given the lack of toxicity seen in this study, dose escalation with protons may represent another approach to overcome the radioresistance seen in certain tumor subtypes, such as KRAS-mutant tumors.
In conclusion, proton-based SBRT is feasible and safe. Radioresistant subgroups were identified based on genotype. Future investigations will focus on achieving more durable local control in KRAS-and TP53-mutant tumors. Additionally, further efforts will be needed to determine which clinical situations proton-based SBRT will be best suited for given the myriad of existing liver-directed therapies for metastases. 
